Global Ezetimibe API Market Insights, Forecast to 2028

Ezetimibe is an azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood.
Market Analysis and Insights: Global Ezetimibe API Market
Due to the COVID-19 pandemic, the global Ezetimibe API market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Purity≥98% accounting for % of the Ezetimibe API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Ezetimibe Tablets segment is altered to an % CAGR throughout this forecast period.
China Ezetimibe API market size is valued at US$ million in 2021, while the US and Europe Ezetimibe API are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ezetimibe API landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Ezetimibe API include Dr. Reddy’s Laboratories Ltd., Rochem International Inc, Tecoland Corporation, Teva API, Changzhou Pharmaceutical Factory, Glenmark Pharmaceuticals, Neuland Laboratories, WUHAN ZY PHARMACEUTICAL CO LTD and Lupin Ltd, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
In terms of production side, this report researches the Ezetimibe API capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Ezetimibe API by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Global Ezetimibe API Scope and Segment
Ezetimibe API market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Ezetimibe API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
Purity≥98%
Purity<98%

Segment by Application
Ezetimibe Tablets
Others

By Company
Dr. Reddy’s Laboratories Ltd.
Rochem International Inc
Tecoland Corporation
Teva API
Changzhou Pharmaceutical Factory
Glenmark Pharmaceuticals
Neuland Laboratories
WUHAN ZY PHARMACEUTICAL CO LTD
Lupin Ltd
Saptagir Laboratories
Chongqing Fuan Pharmaceutical
Lusochimica SpA
Nishchem International Pvt. Ltd
Ind Swift Laboratories Limited
Curequest lifescience LLP
SGMR Pharmaceuticals
Kongo Chemical Co., Ltd.
Production by Region
North America
Europe
China
Japan
India
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E